Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Biocon, Mylan launch...

    Biocon, Mylan launch biosimilar Ogivri for treatment of breast, stomach cancer in Australia

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-08-02T09:45:27+05:30  |  Updated On 2 Aug 2019 4:15 AM GMT
    Biocon, Mylan launch biosimilar Ogivri for treatment of breast, stomach cancer in Australia

    Ogivri is the first trastuzumab biosimilar approved and launched in Australia and available on the Pharmaceutical Benefits Scheme (PBS), Biocon and Mylan said in a joint statement.


    New Delhi: Biotechnology major Biocon and Mylan NV on Thursday launched biosimilar Ogivri, which is used for the treatment of certain breast and stomach cancers in Australia. It is a biosimilar of Hoffmann-La Roche's Herceptin.


    Ogivri is the first trastuzumab biosimilar approved and launched in Australia and available on the Pharmaceutical Benefits Scheme (PBS), the companies said in a joint statement.


    Biocon Biologics Chief Executive Officer Christiane Hamacher said, "We are excited to enable access to Ogivri, in Australia, high-quality biosimilar trastuzumab, co-developed and manufactured by Biocon."


    Read Also: NPPA notices worth Rs 101 crore sent to Biocon, Lupin, Dr Reddys, others for skipping regulatory nod-Minister


    Commercialization of Ogivri by Mylan, in Australia, extends the global footprint of biosimilar trastuzumab, she added.


    "Mylan's investment in biosimilars is an exciting evolution in how we can treat Australian patients. We are delighted that Ogivri enables Mylan, with our partner Biocon, to bring this treatment option to Australian patients with HER2-positive breast and gastric cancers," Mylan Australia Country Manager Sylvain Vigneault said.


    Mylan and Biocon's trastuzumab biosimilar is currently approved in more than 65 countries around the world, including the US, the statement said.


    Mylan and Biocon are exclusive partners on a broad portfolio of biosimilar and insulin products.

    Read Also: Pfizer generic unit Upjohn to merge with Mylan; new entity aims revenue of 19-20 billion Dollar for 2020
    Biocon biosimilar BSE Christiane Hamacher gastric cancers Herceptin insulin products Kiran Mazumdar Shaw Kiran Shaw Mylan Ogivri pharma pharma company pharma news pharma news india Pharmaceutical Benefits Scheme Roche Sylvain Vigneault Trastuzumab 
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      Johnson and Johnson must pay 4 million dollar in punitive damages in latest asbestos cancer trial

      Johnson and Johnson must pay 4 million dollar in punitive damages in latest asbestos cancer trial

      After Abbott, two more Stent makers seek withdrawal of New Gen Stents

      After Abbott, two more Stent makers seek withdrawal of New Gen Stents

      3.36% of about 82,600 drugs samples found to be substandard

      3.36% of about 82,600 drugs samples found to be substandard

      Apollo medical centre in Oman granted hospital status

      Apollo medical centre in Oman granted hospital status

      Aurobindo Pharma receives USFDA approval to manufacture ADHD drug

      Aurobindo Pharma receives USFDA approval to manufacture ADHD drug

      Calcutta HC sets aside Centers decision for strategic sale of Bengal Chemicals

      Calcutta HC sets aside Center's decision for strategic sale of Bengal Chemicals

      Ipca Lab Conferred With the CARE Award

      Ipca Lab Conferred With the CARE Award

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      View All

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 27 May 2022 6:45 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
      verify here.

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
      X
      X